:
Good morning, everyone, and welcome to the health committee.
We're very excited about our committee because we work so well together and get a lot done, and I have to commend all the committee members for that.
I would like to welcome Ruby Dhalla. I haven't had a chance to do that. It's a pleasure to have you on committee, Ruby.
Of course, Mr. Dosanjh, I welcomed you before. It's good to see you here.
And we have Glenn Thibeault. Welcome to our committee as well.
And yes, Monsieur Dufour, I never forget you. So there we go. We welcome Monsieur Dufour just on a general basis when he comes in, and we sing Happy Birthday to him on his birthday.
I'd like to welcome the other visitors we have today. From the Department of Health, we have Diane Labelle, Robert Ianiro, and Athana Mentzelopoulos.
Committee members, today we have Bill before us, and the proposed operational budget in the amount of $15,150 for the committee's study of Bill C-36, an act respecting the safety of consumer products. I put that motion forward to be adopted.
Some hon. members: Agreed.
The Chair: Thank you.
The plan for Bill is as follows. We had said, as committee members, that when legislation came up we would take the legislation first and foremost and get it done. What we're looking at are witnesses from the department today. On Thursday the minister will join us for an hour and then we'll have witnesses on Thursday. And the following Tuesday we have additional witnesses and then we'll do a clause-by-clause. And we're hoping a week today to get the clause-by-clause completed, basically because there's been a lot of study on Bill and there are few amendments, so we as a committee have decided this is the way we want to proceed.
We will begin now with a presentation from Athana Mentzelopoulos. How do you pronounce it?
:
Thank you, Madam Chair, for the opportunity to appear before you to discuss Bill , the proposed Canada Consumer Product Safety Act.
As you know, the introduced this latest version of the legislation in June of this year. Each generation of this bill has been an improvement over the last and reflects the ongoing approach that we take to consumer product safety; that is, we are always looking for the most effective and efficient ways to maintain consumer safety while at the same time ensuring a free flow of goods.
The free flow of goods is related to the post-market regime for consumer safety in Canada. The post-market regime is not something we are proposing to change with this bill. We do not now propose, nor would we propose, that industry be required to seek certification from or otherwise notify the government when new products are introduced for sale in Canada. However, while the vast majority of consumer products are unregulated in this country, we do have a number of regulations and prohibitions in place for consumer products, and we work to promote compliance. Bill would provide an important authority in this regard: a general prohibition against products that pose an unreasonable danger to consumers.
Today the Hazardous Products Act is our legislative basis for consumer safety in Canada. It establishes what is essentially a permissive regime, where a product is allowed in Canada unless it is specifically regulated or prohibited. The general prohibition addresses those products that pose an unreasonable danger to human health or safety.
We expect that industry is already using appropriate standards and risk assessment methods in its evaluation of the safety of its consumer products before being placed on the market.
The general prohibition also supports one of the three key areas that we focus on for improvement in consumer product safety, and that is active prevention.
Modernized authorities developed to correspond to our globalized and post-market consumer product environment will assist us in preventing product safety problems before they arise and before significant risk can develop.
In addition to active prevention, we are focused on targeted oversight and rapid response as key areas for improvement in our consumer safety regime. Bill has new powers requiring manufacturers and importers, upon request by the minister, to provide safety test and study results for their products for verification by Health Canada. This supports targeted oversight while keeping the accountability for safe products with industry.
In addition to record-keeping, the requirement for mandatory reporting of product incidents will help us to respond rapidly when problems develop. Our major trading partners, the United States and the European Union, have already modernized their consumer safety legislation. Bill would bring Canada in line with them on reporting of incidents and recalls.
While the legislation would modernize a very dated system for consumer safety in Canada, we expect to continue to see a very robust voluntary approach to recall by industry. That has also been the experience in the United States.
We know that the vast majority of industry in Canada acts responsibly and we know they value their reputation. Unfortunately, there are still cases where industry either seeks to dismiss a risk or to avoid accountability. In those cases, government requires the tools to take action to protect consumers. Bill would give us the authority to do so.
Our partners have been generous. The United States in particular, owing to the similarities in our industry, continues to help us when it is taking action as a result of the mandatory reporting system and corrective action systems it has in place now.
Frequently, recalls initiated in the U.S. are either simultaneous in Canada or are closely timed. Information from the U.S. has helped us in Canada so that we are able to determine the extent, if any, of recalled products that might be present here. We thank our neighbours for this support and we hope to be more equal partners in consumer safety as a result of this legislation.
Like other elements of the Hazardous Products Act, the current schedule of fines and penalties can lead to the impression that the repercussions of product safety lapses are simply a cost of doing business. For example, the maximum fine under the HPA is now set at $1 million. Bill would raise that to $5 million for some offences or more for offences committed knowingly or recklessly.
The key elements of Bill I know are familiar to many of you on this committee, but there are some important improvements. Specifically, we have made six changes to the legislation since it was before you last.
The first change is a change to authorities for recall and other orders. Previously these authorities would have been assigned to an inspector. Now the minister is made expressly accountable for the authorities. This change addresses the concerns we have heard from some stakeholders that the critical and important authority of a mandatory recall should rest with senior officials.
We have also made two changes in adjusting the wording around inspectors' powers.
The definition of “storage” is now clear in the legislation and it does not apply to goods stored by individuals for their personal use. We have also removed a clause for inspectors to pass over private property so that the provision no longer includes the phrase “and they are not liable for doing so.”
The fourth change--having listened to the committee during previous hearings on this bill and on others--is an improvement to the wording on the provision for an advisory body meant to clarify what was meant by “public advice”.
Fifth, we responded to concerns on review orders, and the bill sets out a 30-day review period.
And finally, a prohibition on BPA, bisphenol A, in polycarbonate baby bottles has been added, ensuring an ongoing high level of protection for consumers.
In summary, the department believes Bill will provide the legislative foundation for active prevention, targeted oversight, and rapid response. The legislation offers certainty and transparency for industry. It gives consumers the information they need to make good product choices. It equips the government with new authorities that are calibrated to a global marketplace and a post-market regime. These new authorities are consistent with health and environmental legislation already in place in Canada. And this legislation would bring us into line with the level of protection provided to consumers in the United States and the European Union.
Those are my comments, Madam Chair, and we are prepared to take your questions.
:
Thank you for being here today, all of you.
Since I come to this rather late and this bill has a long history, I want to ask about what happened in the Senate during the last round. If you know, I'd be happy to hear from you. My question specifically is this. Senator Furey and Senator Banks had introduced some amendments. I'm asking these questions because if we can clarify them here, it might not be held up in the Senate. It might be easier that way.
I don't know what Senator Furey's concerns were. He tells me they were dealt with.
In terms of Senator Banks' concerns, I don't have the information on them, on what they were. Generally speaking, they were that individuals, with respect to disclosure of information, don't have the same protections that businesses or industry might have, where the minister has the discretion and the authority to disclose information.
I'd like you to tell me if you know what Senator Banks had introduced and whether or not that has been dealt with in this. If not, what is the rationale?
:
Thank you for the question.
The provision in the bill that the senator is likely referring to is clause 15, which deals with personal information. The fact is that we do collect some personal information. This provision allows us to share that personal information when we feel it is necessary to do so to deal with a health and safety issue. The amendments that were being proposed at the Senate would, in some cases if not all cases, potentially force us to collect even more personal information.
There was this notion that we should be providing notice and notification to anyone prior to disclosing the personal information. In some cases, we don't have enough information to re-identify that individual; in some cases, we would actually have to be collecting more information in order to contact them and say that we're disclosing information.
Perhaps of more importance is the fact that we don't see many situations in which sharing of personal information, such as the name of the victim in an incident or the details of the person's address, is required in order for us to carry out our actions to better protect health and safety.
Let me give you a concrete example. If we were to come across an incident relating to a particular children's product, what we would really want to be sharing with other jurisdictions is not details of personal information. Rather, we would say that we have evidence to suggest that there was an issue with product X involving a child of six months, and that we were concerned, and we would ask if they were hearing of anything else that would align or match with what we were hearing.
We really didn't feel that any changes or amendments were required. As I said, we in fact came to the conclusion that there is a possibility that we would actually have to start acquiring more personal information.
Perhaps I can just end with a note that the privacy commissioner's office did review the bill and did give it a pass, a clean bill of health, and there were no issues at all with respect to the collection or the management of personal information. As well, the assistant privacy commissioner did appear before the Senate committee to share her comments in those regards.
Thank you.
:
Thank you very much, Madam Chair.
I would like to thank our witnesses for being here with us this morning as part of our first meeting on Bill . Of course, this is not the first meeting that our committee has had regarding the bill because, as you know, we had already studied it once before, but unfortunately, Parliament was prorogued. We therefore have to start all the work over again.
There is the issue of the mail and e-mails that each and every one of us here has received in our offices since our last meeting on the topic, and which deal more particularly with the bill's constitutionality. I imagine that you have also received such comments and concerns.
Can you tell us whether you examined that specific aspect of the bill and whether or not you believe that the bill is constitutionally acceptable?
:
Thank you, Madam Chair.
Thank you, Mr. Thibeault, for the question.
The issue that arose particularly in the Senate centred around the use of inspectors' powers. At the time the explanation and the letter that was tabled with the chair of the committee of the Senate that was hearing the bill confirmed that the Minister of Justice scrutinizes every bill for consistency with the charter, and no such inconsistencies were reported.
The concern appears to be the fact that inspectors, having reasonable grounds to believe that a regulated activity is taking place in a building or a conveyance, may enter to verify compliance or prevent non-compliance solely for the purpose of administering the act, and it seems that the concern that was expressed was why weren't inspectors required to have reasonable grounds to believe that an offence was created and that a judicial warrant was necessary. And in fact the Supreme Court of Canada has recognized the necessity for administrative regimes to verify compliance. That is the type of regime that is set up in Bill , and it goes only to the predominant purpose of ensuring compliance with the statutes and the regulations.
The inspector powers in no way engage an individual's penal responsibility. If it were a matter for a criminal investigation, then yes, either an inspector or a law officer would require a judicial warrant from the court under the criminal court, but that is not what we're talking about in Bill .
:
Thank you for the question.
I have a four-year-old. I think he's just coming out of the eating foreign objects phase--I hope.
What's developed with cadmium today is probably a very good example of the way we might approach product safety differently had we had these provisions in place. I'm speaking in particular of the general prohibition.
With our existing legislative regime, Madam Chair, we have the Hazardous Products Act, which takes a very product-specific approach. So we have, for example, regulations that stipulate limits on the presence of lead. In order for us to be able to take an enforcement approach to cadmium, we need to develop regulations that would stipulate something similar. It would obviously be corresponding to what we would learn as a result of science.
As you've suggested, the problem with cadmium is not wearing it, but ingesting it. At what level does it begin to create a problem? We're not sure. It's an issue that has started to develop recently in a couple of years of cyclical enforcement, because we are on alert for the presence of heavy metals. When we've been testing for lead we've been alive to what might also be other problems with similar products. In 2009 we didn't see a problem with cadmium. We were looking; we were on alert. It is something that has developed this year, in 2010.
For us to be able to develop regulations, as you know, is a necessarily time-consuming process. It requires consultations. If we had the general prohibition in place and we had the scientific basis to determine that at a certain level the presence of cadmium in certain products poses a danger to children or to people in general, then we would be able to actually use the general prohibition as a basis for enforcement. As it stands, in the absence of regulations, we've done what we've done today, which is a voluntary approach. We've used a voluntary approach in the past. It has been productive, but given what we might find in the marketplace going forward, it's probably something we would regulate.
:
I believe it would be most productive to start with the definitions. In the definitions it reads:
“danger to human health or safety” means any unreasonable hazard—existing or potential—that is posed by a consumer product during or as a result of its normal or foreseeable use
Essentially, when we talk about “unreasonable”, we're really trying to get at the notion that there are some consumer products that are inherently dangerous—a chain saw, a kitchen knife, there are others—that we consider to be reasonable dangers because they're part of the utility of the product. In stipulating what, then, would be considered an unreasonable danger, there is already existing, as a result of international standards, a great deal of expertise in industry itself--some of the standards that we've developed. We have implicitly, in our own regulations, to a considerable extent, the definition of what constitutes making sure something is safe. These are all elements of determining whether or not something constitutes an unreasonable danger. Also, through the consultations we're doing on the system for mandatory reporting, we have provided some further elaboration on what would constitute an injury as a result of an unreasonable danger.
So the parameters are well established in the legislation and there is considerable input and advice that we get from the work that goes on in the design industry and in other jurisdictions as well as here.
:
Yes, if I may, Madam Chair.
The Chair: Madame Labelle.
Ms. Diane Labelle: The procedural safeguards that are implied in that question are dealt with in the legislation and in the legal system.
Officials, including the , who exercise powers granted to them in a statute enacted by Parliament--and in this case it would be Bill --are compelled by law to act reasonably. That is to say, they must make decisions with impartiality and fairness. Fairness requires them to act reasonably and to afford procedural protection to the person who is affected by their decision. Officials, including the minister, cannot act in an arbitrary manner. And as I've mentioned, under Bill C-36 this protection is afforded to a person requesting a review of an order.
I would like to add that the legal requirements--the principles of administrative law--do not require that every appeal or review mechanism be structured like courts or quasi-judicial tribunals in order to ensure procedural fairness. And while the minister designates the review officer, once the officer is designated he or she makes the decision and cannot be dictated to, although they can take into account guidelines and departmental policies in making a decision.
:
Thank you, Ms. Labelle.
We're about to go into our five-minute second round, but I'm going to make an announcement now. Because members of Parliament start their day early and we have to bring in lunch for the members only, I'm going to encourage members, as they're questioning, to go to the back and grab their lunch. This might be the only opportunity to do that until late this evening, so I wanted to remind you that lunch is for the members only, at the back.
We will now go into the second round, five minutes. That means two and a half minutes each for question and answer, and I'm going to be very strict.
We'll start with Dr. Duncan. Go ahead.
:
Thank you, Madam Chair, for the opportunity to perhaps clarify those provisions further.
Let me begin with clause 15, which deals, obviously, solely with personal information. Clause 15 will basically allow the minister to share information with other persons or governments involved in the types of activities we at Health Canada are involved in to protect the health and safety of Canadians. In this particular case, the focus is specific to consumer products and agencies involved in consumer product safety. So this really gives us the ability to share personal information in situations where we feel that it is necessary—again, with other government agencies—to carry out our duties.
On the earlier question relating to why we have the word “serious” only in clause 15 and not “serious and imminent”, if the wording was “serious and imminent”, both of those conditions would have to be met. It would constrain us in our ability to share information, since both of those conditions would have to be met.
Clause 16 deals with confidential business information. In order for us to share that type of information, we require confidentiality agreements to be in place with the parties with which we share that information. Again, the information we would share would be related information that is required for us to carry out our business. It's again related to health and safety and consumer protection.
Clause 17 is very similar to clause 16 except that it would be the sharing of confidential business information without a confidentiality agreement in place. The clause is there to deal with situations in which there is a very serious and imminent danger and we don't have time, perhaps, to get a confidentiality agreement in place if it doesn't exist. There is an urgent need for intervention, and we want to share that information to better protect the health and safety of Canadians and take immediate action. In fact, it was also an amendment made at this committee that required that of us if there wasn't a confidentiality agreement in place. There is a requirement now in the bill for the minister to provide notice to the owners of that confidential business information within one business day after disclosure of that information.
I hope that helps clarify those three provisions.
:
Thanks very much, Madam Chair.
Thank you very much for being here with us this morning.
I know this is a bill that everybody around the table is anxious to see move forward.
In your opening remarks you commented that there are new powers in Bill requiring manufacturers and importers, upon request by the minister, to provide safety test and study results for their products.
Now that the minister has discretionary powers and can ask for safety testing and so on, what would trigger that request, to begin with, and then how would the process work after it has been triggered? What will the minister make her decision on to determine whether or not there is a danger?
:
Do you mind if I continue to use the cadmium example?
Mrs. Cathy McLeod: Sure.
Ms. Athana Mentzelopoulos: Okay, thank you.
Right now with cadmium we do have some regulations pertaining to the use of cadmium in surface coatings, ceramic glassware, but we do not have established in regulation an allowable limit or any restrictions on the presence of cadmium, for example, in children's jewellery.
With the Hazardous Products Act we really are required to stipulate in specific regulations that are targeted to particular uses or particular products. In order for us to have the basis to take enforcement action.... For example, having found this year the presence of cadmium in children's jewellery, the only way our inspectors can take action on that is if they have the basis in regulation.
We may proceed under the Hazardous Products Act to develop the regulations that would provide that basis for action. As you probably are aware, the minister released this morning a request that industry take a voluntary approach and avoid any products that have that or not use the substance.
In the context of the Canada Consumer Product Safety Act, this legislation, it would be in particular the general prohibition that would allow us the parameter to take action. So if we knew, for example, that cadmium above a certain limit in a particular product—because it is likely to be mouthed or sucked or chewed by a young child—would or could pose a health problem and unreasonable danger, we could use the provision of the general prohibition as the basis for our inspectors to act very quickly and to move forward with a recall, whether it would be mandatory, which we would have the provisions for in the legislation, or voluntary, where we have a company that says yes, they recognize the problem and they move quickly to recall the product.
So it comes back to whether you have a very narrow product-specific focus, as we do now with the Hazardous Products Act, or the ability to take action when you've determined that in fact there is a danger to human health or safety more broadly.
:
I would characterize the feedback generally as quite positive in the context, for example, of the general prohibition. The requirements that we are placing are requirements that already exist in large part. They are things that industry is aware of because of the results of decisions, for example, in liability cases that have been before the courts.
As I've said, we have an industry in Canada that largely values its reputation, wants to ensure it's providing safe products. The general prohibition really codifies those requirements and makes it transparent. It helps to build a level playing field.
In many respects, the provisions that we have in this legislation are already in place in other jurisdictions as well. So given the global nature of the marketplace, we have companies in Canada who are already subject to mandatory reporting provisions, for example, in the United States. So for many of the players in industry, they are familiar with the kinds of provisions, and if not the specific provision, they're already working to ensure they have safe products, and they appreciate the level playing ground.
At the moment we have a system in place for tracking consumer complaints, and I believe it's a robust system. We have to build on that system, because for mandatory reporting we expect we will be receiving quite voluminous raw data. Whenever there is a serious incident, there will be a requirement upon industry to provide a report. We're currently building that system. We have a lot to learn—and we are learning it—from the United States; they've already implemented their system. We have worked closely with them and studied how it has gone for them, and all of that is feeding into the design of our own system.
We're also consulting. We first issued a kind of consultation paper on what that parameters would be for the mandatory reporting system; it is on our website now. We've been using it as a basis for a quite considerable discussion that Mr. Ianiro has had with various industry players. We're starting to receive comments on it. We were asked, actually, to extend the comment period and have done so. It lays out what we would expect our regulatees to report on and starts to define the parameters. Once the consultation period closes, this will all feed into the design of the system.
Did you want to add anything, Robert?
:
I've been called worse; don't worry.
I looked at the Library of Parliament summary on the history of this section and at Senator Banks' amendment. It talks about essentially providing the same kind of protection to personal information that you provide to corporations or businesses. Why is it so difficult for you to draft it in a way that provides the same protection? When you first share it with a person, or a government in the position of having an obligation for the protection of health and the like, why couldn't you have the same prohibition that it not go public? And if it does go public, Banks' amendment provided you at least six months to notify the person, not just one day, because you had no agreements with the individual.
I'm wondering why it is that you can't provide that protection. The scenario that you paint, Mr. Ianiro, isn't the only scenario wherein you might be sharing information about people. It's not just a six-year-old child who has some problem and you simply don't give their address or name and just share the information. The scenarios could be extremely difficult and complicated.
I'm not satisfied that Banks' amendments are unreasonable, and if you can't satisfy me, we may end up introducing those amendments here.
When you came to brief me, I hadn't looked at the provisions. I simply thought that what you were saying was eminently reasonable. Now I look at the provisions and I look at what he was seeking, and it's not unreasonable. He's not preventing you from sharing information; he is simply saying to you, please give them the same protection: that first you share the information, if it's not that serious, with the proviso that it not be made public, as you do in clause 16, and then, if you have to share it, you have not just one day but six months to notify the person.
:
Given my previous statements that for the most part we have a very responsible industry in this country, I think the tangible impacts of this legislation would probably be marginal for most of Canadian industry, especially given, as I mentioned, that there's already a requirement in other jurisdictions and that much of our industry involves international players, so they do exercise such things as document retention. They're already responding to requirements, for example, for mandatory reporting in other jurisdictions.
There are some quite specific requirements. For some in industry, the requirements will be new, but the design, for example, of mandatory reporting is really oriented to make sure we have a system that's efficient and user-friendly. The requirements will be clear.
We have also taken it as a bit of a principle to aim at the highest levels of trade; for example, if I may come back to the clause 12 authority, in which the minister has the authority to request test results, we've targeted that at the higher levels of trade--importers and manufacturers--where the responsibility really ought to lie, rather than having such a requirement at, for example, the retail level.
I think we've calibrated it to where the accountability lies in the supply chain, and we've also tried to make sure that we've calibrated the requirements to what different levels in the supply chain are capable of.
In terms of an overall benefit, certainly I would come back to the level playing field. In terms of codifying the requirements to ensure safe products through the general prohibition, these are requirements that exist now. This makes it clear for anyone in industry that they have a responsibility to ensure that the products they're selling to Canadians are safe.
:
Thank you for that question.
There is no doubt that there is a broad range of players, and the supply chain is quite extensive. If you go back to the uppermost level, it definitely includes designers. How we've structured the general prohibition in a statute is by refocusing the emphasis on creating that safety net again, to deal with products that may not have specific requirements or a specific regulation, to take into consideration safe design, to know what you're using in your products, and to consider their reasonable and foreseeable use.
As per some of my earlier remarks, we do understand and appreciate that we need to give practical tools and guidance to industry in the way of handbooks, guidance documents, and policies. There are a lot of international standards in place, as well, that we would be leveraging. I indicated as an example the ISO/PC 243 standard, which does take that broad look at consumer product safety--to factor in design, to factor in manufacturing protocols, and to look at quality assurance. All of these things have been built in and will continue to be built as part of the broader framework of the legislation.
:
I'm trying once again to wrap my head around the amendment. I can perhaps think of an example in which, if we're informed by a mother in Toronto that her child had an issue with their crib—a drop-side crib, for example—and she reported those details to us, the amendment that's being proposed is that if, for whatever reason, we needed to disclose personal information with another agency or with a provincial or another government about the specifics of that incident, within six months of that disclosure we would have to inform Mrs. Smith that we're disclosing that information.
The issue is that we may not have enough information from Mrs. Smith originally to contact her, and second, if she's not there, then we actually cannot share the information.
From our perspective, from an administrative perspective, it's quite difficult. Again, there are other protections and provisions that exist.
From an operational perspective, we don't deal a lot with personal information, but if this type of amendment were to be made in this legislation, it potentially sets a fairly significant precedent wherever there are other agencies collecting perhaps much more personal information. That would be very difficult and very onerous to manage, and in some cases potentially impossible.
:
I'll ask Robert to fill in the blanks. He was there personally during some of the discussions.
Essentially, there was a recognition that we needed more resources amongst our cadre of inspectors. We've done the analysis to ascertain, for example, where we have.... We want to go where the work is, essentially.
In my own travels recently, as the new DG, I visited with the regions. We don't necessarily have a uniform number of inspectors associated with each region. In British Columbia there is a lot of volume with imports, and we need to make sure we're resourced appropriately. It's the same in Ontario; a considerable extent of industry is found in Ontario. Obviously we would have--and this is the case--more resources in Ontario than we might find in areas where, for example, there's less industry, less import activity. In Quebec as well we have obviously larger numbers; it correlates to going where the work is and making sure that we're addressing the need.
Did you want to add to that, Robert?
I think part of the answer also is that we've been focusing a lot around solely increasing our capacity of inspectors, which is clearly very important. We are doubling that capacity. By the fifth year of the action plan, 2012-13, in fact we will have overall doubled the entire complement in consumer product safety. We actually will have increased by about 125 employees.
I think it's important to recognize that we also are hiring more analysts to do testing and verification at our laboratory. With the introduction of the general prohibition, there's going to be a lot more research, hazard evaluations, hazard assessments, risk assessments. We're bringing in mandatory incident reporting. We need to have people sitting behind computers triaging the data, analyzing the data. These are all individuals beyond and in addition to the inspectors.
So it's a fairly broad complement of new employees. Inspectors are obviously very critical. We have those who would be devoted to risk assessment, those devoted to standards development. I think also a very critical piece, given the post-market regime of consumer product safety in Canada and worldwide, is the critical importance of outreach. There are also resources and new staff devoted to outreach. That includes outreach to industry in terms of understanding their obligations, as well as outreach to consumers, since we all have a role to play. As regulator, obviously, as government we have a role to play. Consumers have a role to play. Obviously manufacturers and industry have a role to play.
So it's much, much broader than just inspectors.
:
I would say that given how it's subsequently defined in some of the policy elaboration we're doing, including through the consultation we're doing on mandatory reporting, no, it's not too broad.
I think that in program delivery we are always going to have a responsibility to provide precision, to be transparent to our regulatees, to provide the policy elaboration. But it does give the scope within, for example, reasonable and foreseeable use.
You mentioned you have a three-year-old daughter. We have toy experts whose life is literally to try to look at toys through the eyes of children and imagine all the various ways they can get at them, pull them apart, and make something that wasn't previously a problem into a problem.
So in terms of trying to anticipate the unexpected, as you say, we do need some latitude. And we get a lot of advice from legal colleagues on this. We have to provide the precision to give transparency so that regulatees know what it is we expect.
:
Maybe I can just give a few other examples of wording or terms that are used in other statutes in other countries that would be analogous to our “danger to human health or safety”.
One of the risks of providing any more specificity is the very nature of the general prohibition and the definition of “danger to human health or safety” is to create that safety net to deal with unforeseen hazards, unregulated products, unregulated hazards.
The European Union has what is referred to as a general product safety directive, where they basically say you can only manufacture and sell safe products. We talk about not being able to manufacture, import, advertise, or sell something that poses a danger. The United States in their Consumer Product Safety Act basically defines a “substantial product hazard”.
So there are analogous definitions and terminologies that are used worldwide, and they are for the exact same reasons as what we would have. I think the simple answer would be we don't think it's too broad and it is required to support the general prohibition in the manner that we've explained.
Mr. Glenn Thibeault: Thank you.
The labelling you're referring to, I would suspect, not having all the details, is reminiscent of labelling that is in place under Proposition 65 in the state of California, whereby you're required to label pretty much any product that contains any substance that is a known carcinogen, mutagen, or reprotox.
What I find a bit intriguing and perhaps bizarre in this situation is that it's about potentially killing birds. All I could suggest is that I think it's stemming from overheating frying pans. There is a certain chemical in the frying pans, which is often what's called PFOS. I'm not even going to try to give you what that stands for, but I'm pretty sure it's perfluorinated octanal sulfonate. It is something that's used in non-stick. If you put your frying pan on a stove for extended periods of time at high heat, it will release these fumes, and they could potentially kill birds.
I think we would probably be a bit more concerned if it were.... This is not to suggest that I'm not a bird lover, but we obviously would be more concerned with human health, with respect to Bill , which is what we're here to speak to you about.
:
Exactly. There are a couple of elements. The first thing is—we didn't raise this, and it didn't come up in any of the questions—that we have new requirements in Bill that don't currently exist under the Hazardous Products Act. These relate to false and misleading claims relating to certification or health and safety claims. If it is indicated that something meets standards of CSA, the Canadian Standards Association for electrical safety...those types of things would be prohibited. So there are some new labelling and misleading and false claim requirements under the bill.
Speaking specifically to what we would do if we got that complaint, clearly we would need to identify whether it falls within the scope of the act. Clearly in this case, a frying pan does; it is an unregulated product. If it contained a substance of concern and we did a risk assessment and determined that there was an exposure to that substance and that therefore potentially it created a danger to human health or safety, we would have the ability.
It's an interesting example, because it's an unregulated product. Currently, under the HPA it would be very similar and analogous to the cadmium example we've used. Going forward, under Bill , if there is a substance of concern that is found in the consumer product and there is exposure to that substance, then we would have the ability and the authority to take action.
The exposure is critical, because you could have a substance in a product that isn't accessible: there is no exposure; it isn't available. And it's only through that exposure that there actually could be a health concern.
:
Thank you, Madam Chair.
I haven't got a copy of the Privacy Act in front of me, but I've dealt with the Privacy Act and the Access to Information Act for a number of years. The Privacy Act has certain provisions, of which section 8 concerns disclosure without the consent of the individual. The premise is that you have to have the consent of the individual, save and except certain examples that are set out in section 8 of the Privacy Act. One of them, and it's subject to a new act of Parliament, is that you have the authority. And what this bill is attempting to do is to provide the authority to provide without consent. However, that does not usurp the other provisions in the act that govern the protections afforded to the individual in the disclosure of personal information.
For example, there is still the provision that if there is to be disclosure subject to a subpoena, there is disclosure in the public interest. Those continue to apply. But as my colleague Diane Labelle has noted, the Supreme Court of Canada has noted that the Privacy Act has a quasi-constitutional status: the Supreme Court of Canada decision of Dagg.